Showing results (691-700 of 758) with videos related to

Sort By:
Pageof 76
Plos One|December 20, 2021
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort studyPiero Ruggenenti, Fabiano Di Marco, Monica Cortinovis, et al.
Journal of Hypertension|March 1, 2014
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource SettingsPietro A Modesti, Piergiuseppe Agostoni, Charles Agyemang, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 11, 2017
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKDDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 31, 2013
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trialHiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, et al.
Transplantation|July 9, 2004
A comparative prospective study of two available solutions for kidney and liver preservationPaola Pedotti, Massimo Cardillo, Paolo Rigotti, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Nature Reviews. Nephrology|January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal diseaseRichard J H Smith, Gerald B Appel, Anna M Blom, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
Pageof 76